Nasdaq · Healthcare
Kura Oncology, Inc. (KURA)
As-reported financials and recent SEC filings for Kura Oncology, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$67.5M
Net income
$-278.7M
Net margin
—
Diluted EPS
$-3.18
ROE
-160.0%
P/E (TTM)
—
Market cap
—
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0 | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-303.6M | $-193.2M | $-165.8M | $-139.9M | — |
| Net income | $-278.7M | $-174.0M | $-152.6M | $-135.8M | $-130.5M |
| Diluted EPS | $-3.18 | $-2.02 | $-2.08 | $-2.03 | $-1.97 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →1442026-06-18
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →Largest Healthcare peers
Go deeper on KURA
Search Kura Oncology, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.